Leah Zoe Gibson Rand

Leah Zoe Gibson Rand

Auto-generated profile, based on publicly available information

Leah Zoe Gibson Rand

Brigham and Women’s Hospital

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Health Affairs
Verified
Journal Article
Closed access
LRLeah Z. Rand
Leah Z. Rand
AKAaron S. Kesselheim
Aaron S. Kesselheim
Researchers and policy makers in the US are exploring the implementation of health technology assessment and value-based pricing to negotiate drug prices and limit spending. Objections made to the quality-adjusted life-year (QALY), the most frequently used health economic outcome for such assessments, are a barrier to the adoption of these tools. This literature review identifies and addresses the range of criticisms made against QALYs. Methods-based criticisms require attention from stakeholders to address well-known shortcomings of the QALY and ensure consistency. Ethical criticisms, however, do not apply only to the QALY and require political decisions about societal values. Understanding and overcoming criticisms of the QALY to enable its use as part of health technology assessment and value-based pricing will be crucial as US policy makers seek to address high drug costs and health care spending.

27 September 2023 in Health Economics, Policy and Law
Verified
Journal Article
Open access
PDF file
VCVictoria Charlton
Victoria Charlton
MDMichael J DiStefano
Michael J DiStefano
PMPolly Mitchell
Polly Mitchell
LMLiz Morrell
Liz Morrell
LRLeah Rand
Leah Rand
GWGry Wester
Gry Wester
It is acknowledged that health technology assessment (HTA) is an inherently value-based activity that makes use of normative reasoning alongside empirical evidence. But the language used to conceptualise and articulate HTA's normative aspects is demonstrably unnuanced, imprecise, and inconsistently employed, undermining transparency and preventing proper scrutiny of the rationales on which decisions are based. This paper – developed through a cross-disciplinary collaboration of 24 researchers with expertise in healthcare priority-setting – seeks to address this problem by offering a clear definition of key terms and distinguishing between the types of normative commitment invoked during HTA, thus providing a novel conceptual framework for the articulation of reasoning. Through application to a hypothetical case, it is illustrated how this framework can operate as a practical tool through which HTA practitioners and policymakers can enhance the transparency and coherence of their decision-making, while enabling others to hold them more easily to account. The framework is offered as a starting point for further discussion amongst those with a desire to enhance the legitimacy and fairness of HTA by facilitating practical public reasoning, in which decisions are made on behalf of the public, in public view, through a chain of reasoning that withstands ethical scrutiny.

1 April 2021 in Value in Health
Verified
Journal Article
Closed access
LRLeah Z. Rand
Leah Z. Rand
AKAaron S. Kesselheim
Aaron S. Kesselheim

16 May 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
WFWilliam B. Feldman
William B. Feldman
LRLeah Z. Rand
Leah Z. Rand
DCDaniel Carpenter
Daniel Carpenter
MRMassimiliano Russo
Massimiliano Russo
ABAnushka Bhaskar
Anushka Bhaskar
AKAaron S. Kesselheim
Aaron S. Kesselheim
Building trust in public health agencies like the US Food and Drug Administration (FDA) has become a key government priority. Understanding the roots of FDA mistrust is important if the agency is to develop targeted messaging and reforms aimed at building confidence in the agency. We conducted a survey of 2,021 respondents in the US probing attitudes toward the FDA. The primary outcome was FDA trust, defined as the mean score that each respondent assigned to the FDA across four prespecified axes: (1) competence and effectiveness; (2) commitment to acting in the best interests of the American public; (3) abiding by the rules and regulations set forth by policy or law; and (4) expertise in health, science, and medicine. On multivariable ordinal logistic regression, FDA mistrust was associated with female gender (odds ratio [OR] = 0.74, 95% confidence interval [CI] 0.62–0.88), rural community (OR 0.85, 95% CI 0.75–0.96), conservative political views (OR 0.77, 95% CI 0.74–0.81), worse self‐reported health (OR 0.89, 95% CI 0.80–0.98), lower satisfaction with health care received (OR 0.63, 95% CI 0.56–0.71), less attention to health and science news (OR 0.72, 95% CI 0.64–0.80), and not having children under the age of 18 (OR 0.72, 95% CI 0.60–0.86). These findings underscore the challenges faced by US political leaders in convincing a heterogeneous American public to trust the FDA. The FDA should develop and deploy targeted outreach strategies to populations with lower levels of trust and strengthen internal processes that minimize biases and ensure sound decision‐making.

1 September 2021 in Journal of Managed Care & Specialty Pharmacy
Verified
Journal Article
Open access
LRLeah Z Rand
Leah Z Rand
AKAaron S Kesselheim
Aaron S Kesselheim
During the Trump administration, members of Congress and the administration proposed the introduction of international reference pricing (IRP) to Medicare in order to reduce US drug spending by ben...

20 December 2022 in Health Services Research
Verified
Journal Article
Closed access
PDF file
LRLeah Z. Rand
Leah Z. Rand
GMG. J. Melendez‐Torres
G. J. Melendez‐Torres
AKAaron S. Kesselheim
Aaron S. Kesselheim